First human test for new kidney drug

NCT ID NCT02837237

Summary

This early-stage study aimed to check the safety and how the body processes a new oral drug called KBP-5074 in people with severe chronic kidney disease. It involved 11 patients, some on dialysis and some not, to see how they tolerated single doses. The main goal was to gather initial safety information, not to treat the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • KBP Biosciences USA Inc

    Princeton, New Jersey, 08540, United States

Conditions

Explore the condition pages connected to this study.